Skip to main content

Advertisement

SpringerLink
Log in

Ventricular assist devices: Destination therapy or just another stop on the road?

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Ventricular assist devices have attained center-stage recognition with the evolution of the concept of destination therapy, designed as an alternative to cardiac transplantation. However, mechanically induced hemodynamic restoration is accompanied by cellular and biochemical effects that may potentially mediate cardiac recovery. This has raised the fundamental question of whether mechanical assistance is a ‘failure to grave’ option or simply a stop on the road to recovery. The concept of destination therapy as an alternative to transplantation was validated in the Randomized Evaluation of Mechanical Assistance in the Treatment of Congestive Heart Failure trial, but gaps in translating this information to the clinical realm exist because of device limitations of complications and durability. The field of mechanical assistance is progressing rapidly with the introduction of smaller devices that are more durable and have less risk for infection or hematologic aberrancies, which should allow this option to meaningfully enter the clinical arena.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mehra MR, Ventura HO: Heart Failure. In Critical Care, edn 3. Edited by Civetta JM, Taylor RW, Kirby RR. Philadelphia: JB Lippincott Company; 1997:1887–1903.

    Google Scholar 

  2. Hertz MI, Taylor DO, Trulock EP, et al.: The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002, 21:950–970.

    Article  PubMed  Google Scholar 

  3. Mehra MR, Uber PA: The dilemma of late-stage heart failure: rationale for chronic parenteral inotropic support. Cardiol Clin 2001, 19:627–636.

    Article  PubMed  CAS  Google Scholar 

  4. Mehra MR, Uber PA: Emergence of Laplace therapeutics: declaring an end to end-stage heart failure. Congest Heart Fail 2002, 8:228–231, 234.

    PubMed  Google Scholar 

  5. Van Meter Jr CH, Mehra MR: Update on left ventricular assist devices as a bridge to cardiac recovery. Curr Opin Organ Transplant 2001, 6:211–215.

    Article  Google Scholar 

  6. Dipla K, Mattiello JA, Jeevanandam V, et al.: Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998, 97:2316–2322.

    PubMed  CAS  Google Scholar 

  7. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB: Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98:656–662.

    PubMed  CAS  Google Scholar 

  8. James KB, McCarthy PM, Thomas JD, et al.: Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995, 92(Suppl): II91-II95.

    Google Scholar 

  9. Morawietz H, Szibor M, Goettsch W, et al.: Deloading of the left ventricle by ventriclular assist device normalizes increased express of endothelin ET (A) receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure. Circulation 2000, 102(Suppl 3):III188-III193.

    PubMed  CAS  Google Scholar 

  10. Takeishi Y, Jalili T, Hoit BD, et al.: Alterations in Ca2+ cycling protein and G alpha q signaling after left ventricular assist device support in failing human hearts. Cardiovasc Res 2000, 45:883–888.

    Article  PubMed  CAS  Google Scholar 

  11. Heerdt PM, Holmes JW, Cai B, et al.: Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 2000, 102:2713–2719.

    PubMed  CAS  Google Scholar 

  12. Lee SH, Doliba N, Osbakken M, et al.: Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg 1998, 116:344–349.

    Article  PubMed  CAS  Google Scholar 

  13. Mital S, Loke KE, Addonizio LJ, et al.: Left ventricular assist device implantation augments nitric oxide dependent control of mitochondrial respiration in failing human hearts. J Am Coll Cardiol 2000, 36:1897–1902.

    Article  PubMed  CAS  Google Scholar 

  14. Milting H, Bartling B, Schumann H, et al.: Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy-first results of the Halle Assist Induced Recovery study (HAIR). Thorac Cardiovasc Surg 1999, 47:48–50.

    Article  PubMed  CAS  Google Scholar 

  15. Francis GS, Anwar F, Bank AJ, et al.: Apoptosis, Bcl-2 and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail 1999, 5:308–315.

    Article  PubMed  CAS  Google Scholar 

  16. Mancini DM, Beniaminovitz A, Levin H, et al.: Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998, 98:2383–2389. This observational study provides a somewhat pessimistic view of potential weaning of VADs to recovery.

    PubMed  CAS  Google Scholar 

  17. Muller J, Wallukat G, Weng YG, et al.: Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997, 96:542–549. A study of successful VAD explants, this investigation suggests that the presence of autoantibodies directed against the β-receptor can be used to guide weaning from VAD support.

    PubMed  CAS  Google Scholar 

  18. Hetzer R, Muller JH, Weng Y, et al.: Bridging-to-recovery. Ann Thorac Surg 2001, 71(Suppl):S109-S113.

    Article  PubMed  CAS  Google Scholar 

  19. Khan T, Delgado RM, Radovancevic B, et al.: Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation. J Heart Lung Transplant 2003, 22:137–146.

    Article  PubMed  Google Scholar 

  20. Gorcsan J, Severyn D, Murali S, Kormos RL: Non-invasive assessment of myocardial recovery on chronic left ventricular assist device: results associated with successful device removal. J Heart Lung Transplant 2003, 22:1304–1313.

    Article  PubMed  Google Scholar 

  21. Hon JK, Yacoub MH: Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg 2003, 75(Suppl):S36-S41. This paper proposes that using the β-agonist clenbuterol to induce myocardial hypertrophy might maximize the potential for weaning of VAD support.

    Article  PubMed  Google Scholar 

  22. Stevenson LW, Kormos RL, Barr ML, et al.: Mechanical cardiac support 2000: current applications and future trial design: June 15–16, 2000 Bethesda, Maryland. Circulation 2001, 103:337–342.

    PubMed  CAS  Google Scholar 

  23. Rose EA, Gelijns AC, Moskowitz AJ, et al.: Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435–1443. This is a landmark study that investigated patients with severe heart failure (most of whom were inotropic-therapy bound) and demonstrated the feasibility of VAD therapy as an alternative to transplantation. Although laudable, the results were achieved at a cost of significant complication rates.

    Article  PubMed  CAS  Google Scholar 

  24. Deng MC, Young JB, Stevenson LW, et al.: Destination mechanical circulatory support: proposal for clinical standards. J Heart Lung Transplant 2003, 22:365–369. This is a consensus statement that outlines proposed safeguards to prevent the misapplication of this costly and potentially morbid therapy. Many of these recommendations have been endorsed by third-party payers for covering VAD therapy.

    Article  PubMed  CAS  Google Scholar 

  25. Frazier OH: Mechanical circulatory support: new advances, new pumps, new ideas. Semin Thorac Cardiovasc Surg 2002, 14:178–186.

    Article  PubMed  CAS  Google Scholar 

  26. Wieselthaler GM, Schima H, Lassnigg AM, et al.: Lessons learned from the first clinical implants of the DeBakey ventricular assist device axial pump: a single center report. Ann Thorac Surg 2001, 71(Suppl):S139-S143; discussion S144–S146.

    Article  PubMed  CAS  Google Scholar 

  27. Noon GP, Morley DL, Irwin S, et al.: Clinical experience with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 2001, 71(Suppl):S133-S138; discussion S144–S146.

    Article  PubMed  CAS  Google Scholar 

  28. Frazier OH, Myers TJ, Gregoric ID, et al.: Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation 2002, 105:2855–2860.

    Article  PubMed  CAS  Google Scholar 

  29. Rothstein MA, Anderlik MR: The AbioCor artificial replacement heart: bioengineering meets bioethics. J Cardiothorac Vasc Anesth 2002, 16:234–239.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ochsner Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, 1514 Jefferson Highway, 70121, New Orleans, LA, USA

    Mandeep R. Mehra MD

Authors
  1. Mandeep R. Mehra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehra, M.R. Ventricular assist devices: Destination therapy or just another stop on the road?. Curr Heart Fail Rep 1, 36–40 (2004). https://doi.org/10.1007/s11897-004-0015-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-004-0015-6

Keywords

Search

Navigation